Digital Health and HealthTech IPO Performances in the last 12 months: Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health, Kestra Medical

The landscape of healthcare technology and digital health equity markets from late 2024 through mid-2026 has been characterised by a structural revaluation that industry analysts define as the emergence of "Health Tech 2.0". This transition represents a definitive pivot away from the speculative, growth-at-all-costs models of the 2015 to 2021 era, frequently termed Health Tech 1.0, which were often defined by poor unit economics and a reliance on pandemic-driven temporary tailwinds. 
  
The new cohort of companies that have entered the public markets in the last 12 to 24 months, including Tempus AI, Waystar, Caris Life Sciences, Hinge Health, Omada Health and Kestra Medical, are distinguished by significantly more robust business metrics, including a clear path to profitability, deeply embedded artificial intelligence infrastructure and clinical-grade evidence that justifies their inclusion in standard medical workflows.
  
The collective performance of these stocks in 2025 demonstrated a "comeback story" for the sector, with the Health Tech 2.0 cohort adding approximately $36.6 Billion in fresh market capitalisation. This cohort rose by an average of 18% during 2025, matching the gains of the S&P 500 and the NASDAQ Composite, and notably eclipsing the 7% decline observed in the Nasdaq Emerging Cloud Index. 
  
However, as the market progressed into the first half of 2026, the performance of individual entities within this group became highly bifurcated. Investors began to differentiate between companies achieving "Infrastructure Grade" status, those with high net revenue retention and software like margins and those facing traditional healthcare service headwinds or valuation compression due to lingering skepticism from previous market cycles.

Future Outlook: Healthtech Infrastructure in late 2026
  
The strategic focus for digital health in the second half of 2026 is shifting from "experimentation" to "infrastructure". The winners of this next phase will be companies that resemble utilities: trusted pipes, models, and reimbursement mechanisms that are deeply embedded into the healthcare system.
  
Key Predictions for the 2026/2027 Cycle
  
Clinical-Grade Wearables: Consumer health data is becoming clinical-grade, as wearables are pulled into regulated workflows and procurement frameworks (e.g., Kestra Medical's integration into hospital WCD protocols).

GLP-1 Stability: The initial hype around obesity medications is giving way to a focus on durable outcomes. Companies like Omada Health that pair medication with lifestyle coaching will be rewarded for long-term adherence metrics.

AI ROI Mandate: By the end of 2026, AI will no longer be treated as a pilot. Hospitals and payers will expect a positive ROI for all AI applications, and those unable to provide tangible evidence of cost savings or clinical throughput will face valuation compression.

M&A Consolidation: The "patent cliff" and favoUrable antitrust environment will likely lead to a series of high-value acquisitions in the oncology (Tempus/Caris) and MSK (Hinge) segments.

 In summary, the share prices of the digital health and healthtech companies that have IPOed in the last 12-18 months reflect a broader market rebalancing. 
  
While Hinge Health and Tempus AI represent the high-margin, data-rich winners of the current cycle, the operational progress at Waystar, Omada Health and Caris Life Sciences suggests that the valuation gap between "Health Tech 2.0" and the broader technology market is likely to close as these firms prove their durability in a complex regulatory and economic landscape. 
  
The sector's transition from speculative innovation to infrastructure-grade performance marks a structural turning point that promises to redefine the financial and clinical standards of the healthcare industry for the next decade.

Click here to read the report in full https://www.healthcare.digital/single-post/digital-health-and-healthtech-ipo-performances-in-the-last-12-months-tempus-ai-waystar-caris-life